For the quarter ending 2025-09-30, LTRN made $4,522,177 in revenue. -$4,177,423 in net income. Net profit margin of -92.38%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative | 1,912,829 | 1,583,521 | ||
| Research and development | 2,436,971 | 3,068,379 | ||
| Total operating expenses | 4,349,800 | 4,651,900 | ||
| Loss from operations | -4,349,800 | -4,651,900 | ||
| Interest income | 100,921 | 114,745 | ||
| Other income, net | 71,456 | 206,140 | ||
| Net loss | -4,177,423 | -4,331,015 | ||
| Net loss per share of common shares, basic | -0.39 | -0.4 | ||
| Net loss per share of common shares, diluted | -0.39 | -0.4 | ||
| Weighted-average number of common shares outstanding, basic | 10,833,393 | 10,784,725 | ||
| Weighted-average number of common shares outstanding, diluted | 10,833,393 | 10,784,725 | ||
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)